After Attia: A Trust Map for the Post-Epstein Longevity Landscape

The Bloomberg piece, named

In February 2026 Bloomberg published a long piece pairing Peter Attia's name with material from the Epstein files. In March he resigned from CBS News and from David Protein. Both events are public.

The Brief is not in the business of adjudicating allegations against a private individual, and it is not going to start this week. What this issue is interested in is narrower and more useful: a meaningful slice of the longevity audience used to default to one voice for the Sunday-morning longevity read, and that voice is no longer in the rotation. The shelf is short a book. This issue is about the rest of the shelf.

The trust map principle

No single voice should ever hold the position Attia held for many readers. That is a structural argument, not a personal one — it would be true if he had retired peacefully tomorrow.

The same tiered-evidence logic Issue 1 applied to compounds applies to who you read. Tier 1 is the randomized-trial layer; Tier 2 is the open-label and clinical-experience layer; Tier 3 is the mechanism and animal-model layer; Tier 4 is the operator and N=1 layer. A serious reading stack pulls from all four — never from one voice who pretends to compress all four into a single Sunday newsletter. When one voice does that compression, the reader inherits that voice's blind spots, that voice's incentive structure, and that voice's commercial conflicts. A multi-source stack is not just safer epistemically. It is safer commercially.

What follows is one Brief's read of the current map. Five lanes. Two to three voices per lane. One named caution per lane. Treat it as a starting shelf, not a finished one.

The five lanes of trust

Lane 1 — Skeptic counterweight

Eric Topol. His New York Times op-ed and his "Peptide Craze" essay are the loudest skeptic critique in the category, and the loudest skeptic is the one you most need in the rotation. He says no when the evidence is thin. Issue 1 of the Brief opened with his RCT-gap line and conceded it on the merits. That is the relationship a serious reader should have with Topol — quote him, concede where he is right, build the framework that survives his critique.

Caution: Topol's prior runs hard against operator-grade reasoning under uncertainty. He treats the absence of a phase 3 trial as the end of the conversation. The tiered-evidence frame is the answer to that, not a refutation of it.

Lane 2 — Mechanism + body composition

Layne Norton, Don Layman, Stuart Phillips, Mike Israetel. The GLP-1-and-muscle-loss conversation is owned in this lane, not in clinic-blog land. Norton aggregates the literature in plain English; Layman owns the protein-leucine-mTOR thread; Phillips owns the lean-mass research at the academic level; Israetel owns the training-side argument for what it actually takes to defend muscle while in a deficit. The Harvard Science Review's STEP 1 reframing and the Cell Reports Medicine counter-paper both live in their feeds long before they hit the Sunday-morning longevity beat.

Caution: The sports-nutrition lane occasionally over-corrects against any caloric deficit at all. Read the body-comp voices for the muscle question and read another lane for the cardiometabolic question.

Lane 3 — MD framing for non-MDs

Lucy McBride MD, Jake Goodman MD. McBride writes the prescriber's-eye view of GLP-1 patient management — the off-ramp, the side-effect triage, the realistic-expectations conversation a clinic visit cannot fit into fifteen minutes. Goodman publishes the off-ramp framing for patients who started on a GLP-1 and now have to decide whether they are on it for a year, a decade, or for life. His viral essay on that question is the single best non-specialist piece on the topic in the corpus.

Caution: MD-framed content is necessarily within the standard-of-care envelope. It will not engage with RUO compounds, compounding pharmacies, or the gray market. That is a feature for some readers and a gap for others. Pair it with another lane.

Lane 4 — Compound-level practitioner depth

Derek (More Plates More Dates), Andrew Huberman, Nathalie Niddam. Derek publishes per-compound at a depth almost no MD-framed source matches, with caveats and self-experimentation noted. Huberman aggregates and translates academic neuroscience into operator-readable form, with the standard caveats about commercial relationships and over-confident framings. Niddam owns the Khavinson bioregulator lane on Instagram nearly alone — Epitalon, the broader peptide bioregulator program, the literature in translation. Each of these voices publishes operator-grade per-compound content that the MD lane cannot.

Caution: This lane has the highest commercial-conflict density of any lane on the map. Read each voice's disclosure and discount accordingly. The Brief includes itself in this caution, which is why the Conflict Test is one of the five tests from Issue 1.

Lane 5 — Regulatory, FDA, industry beat

STAT News, BioPharma Dive, FiercePharma. The regulatory layer is where the practitioner stack actually lives or dies. RFK at HHS, the Pharmacy Compounding Advisory Committee, the 503(b) outsourcing-facility wars, the kisspeptin and BPC-157 reclassification questions — all of it is reported first by these three. STAT broke the "did Kennedy stack the deck on FDA peptide oversight" piece in late April; BioPharma Dive ran the cleanest read on the same news two days earlier; FiercePharma is the industry-side perspective the other two do not always carry.

Caution: The regulatory beat reports policy and industry maneuvering. It does not translate that into operator decisions. That translation is the Brief's job — and other newsletters' jobs — downstream of the reporting.

What the Brief is and is not in this map

The Brief is the synthesis layer above Reddit and the practitioner layer below Topol. It publishes a per-compound, per-COA, per-protocol-math walkthrough Reddit cannot synthesize and Topol will not write. It is not a replacement for Attia. It does not aspire to be one. The shelf is a five-lane shelf, and the Brief is a single book on a single shelf.

A reader who finishes a Brief issue and stops reading has not built a stack. A reader who finishes a Brief issue and goes to read Topol on the same week has built one rung of a stack. A reader who reads across all five lanes over a month has built a real one.

The honest gaps

Two lanes are missing from the map above, and the Brief is going to name them rather than pretend they are filled.

First, female-physiology-specific peptide research. The cycle-syncing question on GHK-Cu, BPC-157, and TB-500 — the menopausal-transition question on the GH-axis compounds — the pregnancy and lactation contraindications across the category. There are voices working in this space, and the Brief has not yet found one whose stack is consistent enough to recommend without a caveat that swallows the recommendation. If you read someone in this lane whose work survives a ninety-second read, reply.

Second, cardiology and lipids in the GLP-1 era. The cardiovascular-outcomes conversation on the long-half-life GLP-1s is the single most important downstream conversation of the entire weight-loss revolution, and it sits between the body-comp lane (which is not the cardiology lane) and the MD lane (which is the standard-of-care lane, not the operator lane). The Brief does not yet have a default voice for this lane. If you do, send the name.

The map updates as the Brief learns. That is not modesty. That is the procedure.

Next issue tease

Issue 04 — The 39% Question: Synthesizing the GLP-1 Lean-Mass Literature. The Harvard Science Review reframing of STEP 1 and the Cell Reports Medicine counter-paper — read together, fairly, with the age- and composition-stratified risk model nobody else is publishing.

CTA

Reply with one voice you read that I missed. The map updates as the Brief learns.

Colby

—

For research use only. Not medical advice. Compounds discussed are sold for research purposes; nothing here is a recommendation to use them on humans or animals. The team behind The Compound also operates an RUO peptide vendor; that relationship is disclosed on the about page and applied to every issue under the Conflict Test.